A strong,inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients

Roberto Testa, A. R. Bonfigli, C. Sirolla, C. Pieri, M. Marra, R. Antonicelli, S. Manfrini, P. Compagnucci, I. Testa

Research output: Contribution to journalArticle

Abstract

Thrombophilia with a contemporary reduction of fibrinolytic activity has been observed both in diabetes mellitus and hypertension. Previously, we found a relationship between plasminogen activator inhibitor Type 1 (PAI-1) and lipoprotein(a) [Lp(a)] in Type 2 diabetes mellitus patients without complications. We hypothesised that this relationship could be due to a compensatory mechanism able to lower the risk of hypofibrinolysis as found in Type 2 diabetes mellitus. The present work was aimed at investigating the influence of concurrent hypertension and diabetes mellitus on the plasma levels of these two fibrinolytic inhibitors. In addition, other risk factors, known to influence the fibrinolytic parameters, were taken into account. Forty-nine Type 2 non-hypertensive diabetic patients without complications, 47 Type 2 hypertensive diabetic patients without complications, 54 non-diabetic hypertensive subjects without complications as well as 87 control subjects were studied. Plasma concentrations of Lp(a), PAI-1 antigen and activity, and the main parameters of oxidative, lipo- and glycometabolic balance were determined. Significant statistical differences between diabetic and non-diabetic subjects were found concerning triglycerides and antioxidant defence (p <0.01). Analysis of variance showed the F test statistically significant in evaluating the Log PAI-1/Lp(a) (p = 0.02). Correlation analysis between Log PAI-1 antigen and Lp(a) was significant in non-hypertensive diabetic patients, as expected (r = -0.38, p <0.01), and even stronger in hypertensive diabetic patients (P = -0.72, p <0.01). These results allow to hypothesise that the relationship between PAI-1/Lp(a) could be determinant in avoiding vascular complications due to diabetes mellitus and hypertension. (C) 1999, Editrice Kurtis.

Original languageEnglish
Pages (from-to)400-406
Number of pages7
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Volume12
Issue number6
Publication statusPublished - Dec 1999

Fingerprint

Lipoprotein(a)
Plasminogen Activator Inhibitor 1
lipoproteins
diabetes mellitus
hypertension
noninsulin-dependent diabetes mellitus
Diabetes Mellitus
antigens
Hypertension
Type 2 Diabetes Mellitus
blood vessels
risk factors
antioxidant activity
analysis of variance
triacylglycerols
plasminogen activator inhibitors
Antigens
Thrombophilia
Blood Vessels
Analysis of Variance

Keywords

  • Diabetes mellitus
  • Hypertension
  • Lipoprotein(a)
  • Plasminogen activator inhibitor Type 1

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Internal Medicine
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

A strong,inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients. / Testa, Roberto; Bonfigli, A. R.; Sirolla, C.; Pieri, C.; Marra, M.; Antonicelli, R.; Manfrini, S.; Compagnucci, P.; Testa, I.

In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 12, No. 6, 12.1999, p. 400-406.

Research output: Contribution to journalArticle

@article{b861573fc31d43c6a9c490722bb4e4d5,
title = "A strong,inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients",
abstract = "Thrombophilia with a contemporary reduction of fibrinolytic activity has been observed both in diabetes mellitus and hypertension. Previously, we found a relationship between plasminogen activator inhibitor Type 1 (PAI-1) and lipoprotein(a) [Lp(a)] in Type 2 diabetes mellitus patients without complications. We hypothesised that this relationship could be due to a compensatory mechanism able to lower the risk of hypofibrinolysis as found in Type 2 diabetes mellitus. The present work was aimed at investigating the influence of concurrent hypertension and diabetes mellitus on the plasma levels of these two fibrinolytic inhibitors. In addition, other risk factors, known to influence the fibrinolytic parameters, were taken into account. Forty-nine Type 2 non-hypertensive diabetic patients without complications, 47 Type 2 hypertensive diabetic patients without complications, 54 non-diabetic hypertensive subjects without complications as well as 87 control subjects were studied. Plasma concentrations of Lp(a), PAI-1 antigen and activity, and the main parameters of oxidative, lipo- and glycometabolic balance were determined. Significant statistical differences between diabetic and non-diabetic subjects were found concerning triglycerides and antioxidant defence (p <0.01). Analysis of variance showed the F test statistically significant in evaluating the Log PAI-1/Lp(a) (p = 0.02). Correlation analysis between Log PAI-1 antigen and Lp(a) was significant in non-hypertensive diabetic patients, as expected (r = -0.38, p <0.01), and even stronger in hypertensive diabetic patients (P = -0.72, p <0.01). These results allow to hypothesise that the relationship between PAI-1/Lp(a) could be determinant in avoiding vascular complications due to diabetes mellitus and hypertension. (C) 1999, Editrice Kurtis.",
keywords = "Diabetes mellitus, Hypertension, Lipoprotein(a), Plasminogen activator inhibitor Type 1",
author = "Roberto Testa and Bonfigli, {A. R.} and C. Sirolla and C. Pieri and M. Marra and R. Antonicelli and S. Manfrini and P. Compagnucci and I. Testa",
year = "1999",
month = "12",
language = "English",
volume = "12",
pages = "400--406",
journal = "Diabetes, Nutrition and Metabolism - Clinical and Experimental",
issn = "0394-3402",
publisher = "Editrice Kurtis s.r.l.",
number = "6",

}

TY - JOUR

T1 - A strong,inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients

AU - Testa, Roberto

AU - Bonfigli, A. R.

AU - Sirolla, C.

AU - Pieri, C.

AU - Marra, M.

AU - Antonicelli, R.

AU - Manfrini, S.

AU - Compagnucci, P.

AU - Testa, I.

PY - 1999/12

Y1 - 1999/12

N2 - Thrombophilia with a contemporary reduction of fibrinolytic activity has been observed both in diabetes mellitus and hypertension. Previously, we found a relationship between plasminogen activator inhibitor Type 1 (PAI-1) and lipoprotein(a) [Lp(a)] in Type 2 diabetes mellitus patients without complications. We hypothesised that this relationship could be due to a compensatory mechanism able to lower the risk of hypofibrinolysis as found in Type 2 diabetes mellitus. The present work was aimed at investigating the influence of concurrent hypertension and diabetes mellitus on the plasma levels of these two fibrinolytic inhibitors. In addition, other risk factors, known to influence the fibrinolytic parameters, were taken into account. Forty-nine Type 2 non-hypertensive diabetic patients without complications, 47 Type 2 hypertensive diabetic patients without complications, 54 non-diabetic hypertensive subjects without complications as well as 87 control subjects were studied. Plasma concentrations of Lp(a), PAI-1 antigen and activity, and the main parameters of oxidative, lipo- and glycometabolic balance were determined. Significant statistical differences between diabetic and non-diabetic subjects were found concerning triglycerides and antioxidant defence (p <0.01). Analysis of variance showed the F test statistically significant in evaluating the Log PAI-1/Lp(a) (p = 0.02). Correlation analysis between Log PAI-1 antigen and Lp(a) was significant in non-hypertensive diabetic patients, as expected (r = -0.38, p <0.01), and even stronger in hypertensive diabetic patients (P = -0.72, p <0.01). These results allow to hypothesise that the relationship between PAI-1/Lp(a) could be determinant in avoiding vascular complications due to diabetes mellitus and hypertension. (C) 1999, Editrice Kurtis.

AB - Thrombophilia with a contemporary reduction of fibrinolytic activity has been observed both in diabetes mellitus and hypertension. Previously, we found a relationship between plasminogen activator inhibitor Type 1 (PAI-1) and lipoprotein(a) [Lp(a)] in Type 2 diabetes mellitus patients without complications. We hypothesised that this relationship could be due to a compensatory mechanism able to lower the risk of hypofibrinolysis as found in Type 2 diabetes mellitus. The present work was aimed at investigating the influence of concurrent hypertension and diabetes mellitus on the plasma levels of these two fibrinolytic inhibitors. In addition, other risk factors, known to influence the fibrinolytic parameters, were taken into account. Forty-nine Type 2 non-hypertensive diabetic patients without complications, 47 Type 2 hypertensive diabetic patients without complications, 54 non-diabetic hypertensive subjects without complications as well as 87 control subjects were studied. Plasma concentrations of Lp(a), PAI-1 antigen and activity, and the main parameters of oxidative, lipo- and glycometabolic balance were determined. Significant statistical differences between diabetic and non-diabetic subjects were found concerning triglycerides and antioxidant defence (p <0.01). Analysis of variance showed the F test statistically significant in evaluating the Log PAI-1/Lp(a) (p = 0.02). Correlation analysis between Log PAI-1 antigen and Lp(a) was significant in non-hypertensive diabetic patients, as expected (r = -0.38, p <0.01), and even stronger in hypertensive diabetic patients (P = -0.72, p <0.01). These results allow to hypothesise that the relationship between PAI-1/Lp(a) could be determinant in avoiding vascular complications due to diabetes mellitus and hypertension. (C) 1999, Editrice Kurtis.

KW - Diabetes mellitus

KW - Hypertension

KW - Lipoprotein(a)

KW - Plasminogen activator inhibitor Type 1

UR - http://www.scopus.com/inward/record.url?scp=0033367093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033367093&partnerID=8YFLogxK

M3 - Article

C2 - 10782561

AN - SCOPUS:0033367093

VL - 12

SP - 400

EP - 406

JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental

JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental

SN - 0394-3402

IS - 6

ER -